The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure-Reference-Cited by-同舟云学术

The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure

Published:2013-06 Issue:3 Volume:13 Page:302-306
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Jabbour Elias,Kantarjian Hagop,Ghanem Hady,O'Brien Susan,Quintas-Cardama Alfonso,Garcia-Manero Guillermo,Cardenas Marylou,Cortes Jorge

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference26 articles.

1. Current and emerging treatment options in chronic myeloid leukemia;Jabbour;Cancer,2007

2. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia;Kantarjian;N Engl J Med,2002

3. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O'Brien;N Engl J Med,2003

4. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate;Cortes;Clin Cancer Res,2005

5. Survival benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia;Kantarjian;Blood,2006

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy;Frontiers in Oncology;2024-07-29

2. “Sin derecho a gozar del derecho a la salud”: o sistema de saúde da Colômbia desde a perspectiva crítica daqueles que o vivem, sofrem e lutam;Crise global e sistemas de saúde na América Latina;2022-11-22

3. Allogeneic stem cell transplantation for chronic myeloid leukemia in the tyrosine kinase inhibitor era;The Egyptian Journal of Haematology;2022

4. When to consider allogeneic transplant for chronic myeloid leukemia;ADVANCES IN CELL AND GENE THERAPY;2020-08-09

5. A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting;Wiener klinische Wochenschrift;2020-06-12